Alterity Therapeutics Ltd ADR is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders. The company’s current research centers on diseases such as Parkinson’s disease and multiple system atrophy, with a pipeline built around small-molecule drug candidates designed to address underlying disease mechanisms. Its lead programs are aimed at reducing pathological protein aggregation, modulating excess labile iron, and supporting neuronal function in the brain. Alterity Therapeutics also develops biomarker and clinical-stage assets to better understand progression in neurodegenerative conditions. Headquartered in Melbourne, Australia, the company operates in the global pharmaceutical and biotechnology market, where it contributes to ongoing efforts in targeted treatments for complex brain disorders. As an ADR, Alterity Therapeutics Ltd provides U.S. investors access to the company’s ordinary shares through a listed depositary receipt structure.
Website500 Collins Street
Melbourne, VIC, 3000
Australia
What share of all stock conversation is about ATHE?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about ATHE that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% 0 | 87.85% +3.98 | ||
| Bearish | — | — | 0% 0 | 12.15% -3.98 |
Of the messages about ATHE that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 40% | 75.89% | ||
| Analysts | — | — | 60% | 4.26% | ||
| Controversies | — | — | 0% | 0% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 1.42% | ||
| Technical Analysis | — | — | 0% | 18.44% |
Of the messages about ATHE, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 100% | 100% | 73.74% | ||
| Newcomers | — | 0% | 0% | 26.26% |
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States. A link to the live
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.
Investors talking about ATHE also mention